Longitudinal analysis uncovers the link between IgG levels and MG-ADL scores in generalized myasthenia gravis, suggesting potential for targeted therapy.
To explore the longitudinal relationship between immunoglobulin G (IgG) level and Myasthenia Gravis-Activities of Daily Living (MG-ADL) score using semi-mechanistic pharmacometrics modeling with data from clinical studies of nipocalimab in generalized myasthenia gravis (gMG) and healthy volunteers.
No takes yet. Share an insight, caveat, or question.
Mahuwala et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: